A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
ConditionHematologic Neoplasms
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorKyowa Kirin Co., Ltd.
About this trial
KK2430 ("Study Drug") as a potential treatment for people with Hematologic Neoplasms. KK2430 is an experimental drug; it has not been approved for the treatment of any disease by health authorities such as United States Food and Drug Administration (FDA), and this is the first time it will be given to people. The purpose of this Study is to find out more information about KK2430, whether it is safe in humans, how the body processes it, and if it works for treating your condition.
Eligibility criteria
Qualifiers
Participants must be at least 18 years of age at the time of signing the informed consent.
At least 1 measurable diseases based on CT scan or MRI
Renal function values
Participants who have an ECOG PS score of 0, 1 or 2.
Disqualifiers
Medical Conditions
History of prior allogenic transplant.
Presence of Grade 2 peripheral neuropathy with pain.
Impaired cardiac function or clinically significant cardiac disease at Screening
Trial design
Treatments tested in this trial
- KK2430
Treatment groups
72 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov